Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
HIV Clin Trials ; 19(4): 139-147, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30451595

RESUMO

The antiretroviral drug efavirenz (EFV) has been linked to disordered sleep and cognitive abnormalities. We examined sleep and cognitive function and subsequent changes following switch to an alternative integrase inhibitor-based regimen. Thirty-two HIV-infected individuals on EFV, emtricitabine, and tenofovir (EFV/FTC/TDF) without traditional risk factors for obstructive sleep apnea (OSA) were randomized 2:1 to switch to elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) or to continue EFV/FTC/TDF therapy for 12 weeks. Overnight polysomnography and standardized sleep and neuropsychological assessments were performed at baseline and at 12 weeks. No significant differences in change over 12 weeks were noted between the two arms in any sleep or neuropsychological test parameter. At entry, however, the rate of sleep disordered breathing (SDB) was substantially higher in study subjects compared to published age-matched norms and resulted in a high assessed OSA rate of 59.4%. Respiratory Disturbance Index (RDI), a measure of SDB, correlated with age- and education-adjusted global neuropsychological Z-score (NPZ) (r = -0.35, p = 0.05). Sleep Maintenance Efficiency, Wake after Sleep Onset, REM Sleep and RDI correlated with domain-specific NPZ for learning and memory (all p-values ≤ 0.05). Among HIV-infected individuals on EFV-based therapy and without traditional risk factors for OSA, sleep and neuropsychological abnormalities do not readily reverse after discontinuation of EFV. High baseline rates of SDB and abnormalities in sleep architecture exist in this population correlating with neuropsychological impairment. The role of HIV immuno-virologic or lifestyle factors as contributing etiologies should be explored. OSA may be an under-recognized etiology for cognitive dysfunction during chronic HIV.


Assuntos
Benzoxazinas/efeitos adversos , Benzoxazinas/uso terapêutico , Doenças do Sistema Nervoso Central/induzido quimicamente , Infecções por HIV/tratamento farmacológico , HIV-1 , Transtornos do Sono-Vigília/induzido quimicamente , Adulto , Alcinos , Fármacos Anti-HIV/efeitos adversos , Fármacos Anti-HIV/uso terapêutico , Benzoxazinas/administração & dosagem , Cobicistat/administração & dosagem , Cobicistat/uso terapêutico , Ciclopropanos , Emtricitabina/administração & dosagem , Emtricitabina/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tenofovir/administração & dosagem , Tenofovir/uso terapêutico
2.
Pac Health Dialog ; 14(1): 182-7, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19772156

RESUMO

The Republic of Palau has a well-run public health system despite being a small, relatively isolated island country with limited resources and limited funds. Using interviews with key informants, participant observation in clinics throughout Palau, and a review of available reports, we identified themes locally regarded as central to the success of Palau's public health programs. These include a comprehensive definition of "health," a sense of community-ownership, creative efforts to identify effective behavioral modification techniques, efforts to improve internal training and infrastructure, quality assurance, the importance of leading by example, and a general willingness to collaborate and compromise. We suggest that recognition and application of these concepts would improve not only the public health systems and primary care settings of other Micronesian nations, but also help correct the increasingly dysfunctional healthcare of the United States.


Assuntos
Atenção à Saúde/organização & administração , Recursos em Saúde/provisão & distribuição , Prática de Saúde Pública , Saúde Pública/educação , Saúde Pública/normas , Comportamento Cooperativo , Difusão de Inovações , Humanos , Palau
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA